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Abstract
Background. Elevated inflammation is a proposed mechanism relating chronic diseases to cognitive 
dysfunction. The objective of this study was to test the hypothesis that greater levels of inflammation, 
as measured by the proinflammatory cytokine interleukin-6 (IL-6) and C-reactive protein, are associated 
with faster rates of cognitive decline among cognitively intact community-dwelling older women.
Methods. We analyzed 336 women from the Women’s Health and Aging Study II. Cognitive 
assessments were performed at baseline and every 18–36 months, and included the following 
domains: immediate and delayed memory (Hopkins Verbal Learning Test), psychomotor speed 
(Trail Making Test, Part A), and executive function (Trail Making Test, Part B). Aggregate measures 
of IL-6 and C-reactive protein, based on the average from visits one and two, were analyzed 
categorically. Random effects models were employed to test the relationship between tertiles of 
each inflammatory marker and changes in cognitive domain scores over 9 years.
Results. Moderate and high levels of IL-6 predicted early declines in psychomotor speed by 1.0 
connection/min per year. There were no differences in baseline scores or rates of change across 
tertiles of IL-6 in memory or executive function. No differences were observed across tertiles of 
C-reactive protein for all cognitive domains.
Conclusions. Higher levels of serum IL-6 were associated with greater declines in psychomotor 
speed over 9  years. This finding could suggest that elevated IL-6 may result in microvascular 
changes that may lead to damage of myelin sheaths that line neuronal axons, leading to decreased 
neuron propagation and impaired processing speed; however, mechanistic studies are needed to 
evaluate these hypotheses.
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Inflammation has been linked to both cardiovascular disease 
(CVD) and diseases of the brain, including vascular dementia and 
Alzheimer’s dementia (AD). With the aging of the U.S. population 
and greater incidence of chronic diseases compared to infectious dis-
eases, recent literature has focused on exploring cardiovascular risk 
factors for cognitive decline and dementia. Elevated inflammation 
has been suggested as one possible mechanism relating such chronic 
diseases to cognitive dysfunction. Inflammatory markers have also 
been implicated in the development of amyloid beta peptides, a pri-
mary component of amyloid plaques that are the hallmark charac-
teristic of AD.
An increasing number of studies have explored the associations 
between inflammation and dementia outcomes; however, far fewer 
have characterized inflammation in relation to preclinical domain-
specific cognitive declines. In a cohort of Japanese Americans, par-
ticipants in the highest quartile of C-reactive protein (CRP) had a 
three times greater risk for all-cause and cause-specific dementias (1). 
Similar results were observed in a population-based sample from the 
Netherlands (2), the Framingham Study and Uppsala Longitudinal 
study of Adult Men (3). Other studies have found that inflammatory 
markers, such as CRP and proinflammatory cytokine interleukin-6 
(IL-6), did not independently predict a greater risk for dementia, but 
that in combination with other elevated inflammatory markers, a 
greater risk for dementia was observed (4).
Fewer studies have examined the association between inflamma-
tion and domain-specific cognitive declines. In a longitudinal study 
of older adults, inflammation was associated with global cognitive 
decline, but not declines in memory, intelligence, or processing speed 
(5). Another longitudinal study of aging examined the impact of 
inflammation on delayed memory recall, but did not include a test 
of immediate memory (6). Prior analyses have not studied inflamma-
tion-related cognitive decline in the domains of executive function 
and psychomotor speed, both of which are important to functional 
independence (7).
Inflammation may be a precipitating factor linking vascular dis-
eases and dementia and age-related cognitive decline. The objective 
of this study was to test the hypothesis that higher levels of inflam-
mation, as measured by serum IL-6 and CRP, are associated with 
faster rates of decline over 9 years in three major cognitive domains 
among cognitively intact community-dwelling older women: verbal 




The Women’s Health and Aging Study (WHAS) II is a prospective 
cohort study that followed community-dwelling older adult women 
in Baltimore, Maryland. The primary aim of the study was to iden-
tify the causes and courses of disability. The participants in WHAS 
II were identified and selected randomly from the Health Care 
Financing Administration’s Medicare eligibility list for 12 zip codes 
of Eastern Baltimore City and County. Participants in WHAS II were 
sampled to be representative of the two-thirds least disabled women. 
Inclusion was limited to women aged 70–79 years who had difficulty 
in no or only one area of physical functioning (ie, upper extremity 
function or basic self-care) and had intact cognitive function at base-
line, as measured by a Mini-Mental State Examination (8) score ≥24. 
Specifics regarding this study have been described elsewhere (7,9). 
Written informed consent was obtained from all participants. The 
Johns Hopkins IRB approved all protocols.
Baseline data for WHAS II were collected between 1994 and 
1996. Among the 880 women screened and eligible for WHAS II, 
49.5% agreed to participate. Compared with those participants who 
were enrolled, those who declined to participate had less educa-
tion and fewer diseases but did not significantly differ in race (7). 
Follow-up questionnaires were administered every 18–36 months. 
Data are currently available from six rounds of data collection with 
approximately 9 years of follow-up. Each round was separated by 
1.5 years, except between rounds 3 and 4, which was separated by 
a 3-year interval. Of the 436 women enrolled in WHAS II, 387 had 
complete cognitive data at baseline and 363 had complete cogni-
tive test data for baseline and at least one follow-up visit. Of these, 
25 and 19 were missing baseline IL-6 and CRP values, respec-
tively. Those with missing data were less educated, more likely to 
have CVD and more often nonwhite; however, they were no more 
depressed, overweight, or likely to smoke or drink than the nonmiss-
ing. The final analytic sample included 336 participants with avail-
able baseline IL-6 and CRP data.
Exposure: IL-6 and CRP
Nonfasting blood specimens were collected. A commercial immuno-
sorbent assay was used to measure IL-6 in frozen specimens (High 
Sensitivity Quantikine Kit, R&D Systems, Minneapolis, MN). CRP 
was analyzed at Quest Diagnostics Laboratories (Teteroboro, NJ).
Outcome: Cognitive Test Scores
The cognitive domains assessed include verbal memory (immediate 
and delayed recall), psychomotor speed, and executive function. All 
cognitive tests were administered at baseline and all five follow-up 
visits.
The memory domain was assessed using the Hopkins Verbal 
Learning Test-Revised (HVLT-R) (10). Components include a test 
of both immediate and delayed recall. For immediate recall, partici-
pants were orally presented with a 12-word list to recall in a series 
of three trials. Following a 20-minute delay, participants were asked 
to recall the list. Scoring for the HVLT-R is based on the total num-
ber of correctly recalled words over three trials for immediate recall 
(maximum = 36) and for one trial of delayed recall (maximum = 12).
The psychomotor speed domain was assessed using the Trail 
Making Test, Part A, (TMT, Part A) (11). In a timed test, participants 
were presented with circled numbers 1–25 positioned randomly on 
one side of a paper. Participants were asked to connect the numbers 
in ascending order as fast as they could without taking their pencil 
off the paper. A maximum of 4 minutes was allocated to complete 
the task. Scoring for the TMT, Part A, was based on time (in seconds) 
to completion, with a possible range in scores from 0 to 240 seconds 
(a lower time indicates better performance).
Executive functioning governs goal-directed behavior, including 
initiation and inhibition of a task. The executive function domain 
was assessed using the Trail Making Test, Part B (TMT, Part B) (11). 
Following presentation of the TMT, Part A, participants were pre-
sented with numbers and letters positioned randomly on one side of 
a paper. Participants were asked to connect the numbers and letters 
in numeric-alpha ascending order (1-A-2-B-3-C) as fast as they could 
without taking their pencil off the paper. A maximum of 6 minutes 
was allocated to complete the task. Scoring for the TMT, Part B, is 
based on time (in seconds) to completion of task, with a possible 
range in scores from 0 to 360 seconds (a lower time indicates better 
performance). In keeping with previous literature and to account for 
non-normality of the TMT, Part A, and TMT, Part B, test times were 
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converted to number of connections per minute to capture speed to 
task completion (7).
Covariates
Covariates were selected based on a priori theory, prior literature, 
and univariate analyses suggesting that they were associated with 
both inflammation and cognitive test outcomes. Age (years), educa-
tion (years), and body mass index were modeled as continuous vari-
ables. Race was dichotomized as Caucasian or African American. 
Smoking status was categorized as never, former, or current smoker. 
Alcohol use was dichotomized as yes/no based on the question, “Do 
you usually drink alcoholic beverages, including beer, wine, sherry, 
or liquor, at least once every week?” (9).
Cardiovascular diseases included heart attack or myocardial 
infarction, angina, congestive heart failure, stroke, and peripheral 
artery disease. All diseases and conditions in the WHAS studies were 
adjudicated by two physicians based on examination, medication 
list, radiographs, blood tests, and medical records (9). A standard-
ized algorithm was also used to adjudicate diabetes at baseline (9). 
Hypertension was based on a self-report of a physician diagnosis. 
Depressive symptoms were measured using the Geriatric Depression 
Scale and analyzed continuously (12).
Analyses involving the TMT, Part B (and executive function 
domain [which included the TMT, Part B]) were further adjusted for 
continuous values of the TMT, Part A, to partition out the psycho-
motor speed component and better isolate the executive functioning 
task.
Statistical Analysis
IL-6 and CRP were analyzed categorically. Values were classified 
based on tertile cut points from the analytic sample and defined as 
low, moderate, or high. An aggregate measure, defined as the average 
of IL-6 and CRP values from rounds 1 and 2, was used to determine 
the tertile cut points. The cut points for IL-6 were: low (<2.34 pg/
mL), moderate (2.34–3.42 pg/mL), and high (>3.42 pg/mL). The cut 
points for CRP were: low (≤2.0 mg/L), moderate (2.1–4.90 mg/L), 
and high (>4.90 mg/L). These cut points are consistent with previous 
studies of older adults (6,13).
A longitudinal analysis incorporating random effects for base-
line cognitive function (ie, intercepts) and random effects for change 
(ie, slopes) was conducted. Separate models were run for each of 
the four cognitive tests. An interaction between the inflammatory 
marker and time in the random effects model was used to estimate 
the effect of the inflammatory marker on changes in domain-specific 
cognitive function over 9 years of follow-up. Because of a nonlinear 
trend in rates of cognitive decline, a two-piece spline term was incor-
porated at Year 3 to allow for the rate of cognitive decline to differ 
between Years 1–3 and 3–9 (14). All analyses were performed using 
STATA 13.0 (Stata Corp, College Station, TX).
Results
Table 1 displays the baseline characteristics of the analytic sample 
(n = 336). The mean age (standard deviation,  SD) was 74.0 (2.8) 
years. Most of the sample achieved at least a high-school educa-
tion with the mean education (SD) of the sample being 12.8 (3.2) 
years. Fifteen percentage of the sample was nonwhite. The cohort 
had a relatively high prevalence of hypertension (46.7%) and CVD 
(80.0%), but a low prevalence of diabetes (7.7%). Sixty-six percent-
age of participants were using anti-inflammatory medications at 
baseline. Means (SD) and ranges for baseline cognitive test scores in 
the sample, by tertiles of IL-6, are provided in Table 2 (by tertiles of 
CRP: Supplementary Table S1). Baseline cognitive test performance 
did not differ significantly across tertiles of IL-6 or CRP for any 
of the cognitive tests. The distribution of cognitive test scores by 
tertiles of IL-6 and CRP are shown in Supplementary Figures S1 
and S2, respectively, in the Supplementary Material. Scatter plots 
of cognitive test scores across continuous IL-6 and CRP values are 
provided in Supplementary Figures S3 and S4, respectively, in the 
Supplementary Material.
Annual rates of change between Years 1–3 and Years 3–9 in cog-
nitive test scores are depicted for each tertile of IL-6 in Table 3. No 
differences were observed at baseline or in rates of change across 
tertiles of IL-6 in the domains of memory and executive function. 
On the TMT, Part A, a measure of psychomotor speed, there were 
no significant differences in adjusted baseline cognitive test scores 
across tertiles of IL-6. Individuals with either moderate or high lev-
els of IL-6 experienced a significant annual decline on psychomotor 
speed in Years 1–3, but not during Years 3–9, compared with indi-
viduals with a low IL-6. In Years 1–3, individuals with a moderate 
IL-6 level showed declines in psychomotor speed at an average rate 
of roughly 1.0 connection per minute per year (95% CI: −1.7, −0.4) 
compared with those with low IL-6. Individuals with high baseline 
IL-6 levels showed declines in psychomotor speed at an average rate 
of approximately 1.1 connections per minute per year (95% CI: 
−1.8, −0.5) compared with those with low baseline IL-6 levels dur-
ing Years 1–3.
No differences in baseline measures or rates of change were 
observed across tertiles of CRP for all cognitive domains assessed 
(Supplementary Table S2). A sensitivity analysis, incorporating base-
line anti-inflammatory medication use as a covariate, was performed 
Table  1. Baseline Demographic and Cognitive Characteristics of 
WHAS II Participants (N = 336)
Characteristic Analytic Sample 
(N = 336)
Age, years, mean ± SD 74.0 ± 2.8
Education, years, mean ± SD 12.8 ± 3.2
Nonwhite, n (%) 51 (15.2)
Clinical CVD, n (%) 269 (80.0)
Diabetes mellitus, n (%) 26 (7.7)
Hypertension, n (%) 157 (46.7)
Arthritis, n (%) 84 (25.0)
Difficulty with activities of daily living 22 (6.5)
BMI, kg/m2, mean ± SD 26.5 ± 4.8
Current smoker, n (%) 34 (10.1)
Drinking status, n (%) 112 (33.3)
Anti-inflammatory medication use, n (%) 224 (66.7)
Interleukin-6, pg/mL, mean (IQR) 4.0 (2.2–4.1)
C-reactive protein, mg/L, mean (IQR) 5.1 (2–6)
HVLT—Immediate, words recalled, mean ± SD 23.0 ± 5.0
HVLT—Delayed, words recalled, mean ± SD 8.3 ± 2.6
TMT—Part A, seconds, mean ± SD 45.2 ± 18.5
TMT—Part A, number of connections/min,  
mean ± SD
36.3 ± 12.5
TMT—Part B, seconds, mean ± SD 125.9 ± 68.5
TMT—Part B, number of connections/min,  
mean ± SD
14.1 ± 5.8
Notes: BMI = body mass index; CVD = cardiovascular disease; HVLT = Hop-
kins Verbal Learning Test; IQR = Interquartile range; TMT = Trail Making 
Test; WHAS = Women’s Health and Aging Study.
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and the results were unchanged. The coefficients and inferences were 
unchanged between the demographically adjusted and fully adjusted 
models (Supplementary Tables S3 and S4).
Discussion
In WHAS II, we observed that moderate and high levels of IL-6 pre-
dicted early declines in psychomotor speed by about 1.0 connection 
per minute per year. These findings both contradict and support the 
limited data reported previously on inflammation and age-related 
cognitive decline. Contrary to a study with similarly functioning 
older adult men and women, we found no association between 
inflammation and declines in memory (6). However, our study par-
ticipants may have been healthier by virtue of higher education and 
with fewer comorbid conditions at baseline, which have been found 
to be protective against future cognitive decline and dementia risk 
(15). In a sample of older adults from Amsterdam, researchers found 
declines in processing speed over a 3-year follow-up, but only for 
high levels of α1-antichymotrypsin, not for high levels of CRP or IL-6 
(5). The literature is inconsistent and indicates the need for more 
research examining this association, particularly for specific cogni-
tive domains, to elucidate the mechanistic pathway by which inflam-
mation may influence the risk for and stages of accelerated cognitive 
decline and dementia.
An examination of the impact of inflammatory processes on age-
related risk for cognitive decline, mild cognitive impairment, and 
subsequent dementia is important for identifying how inflammation 
contributes to causal pathways, as well as providing areas for tar-
geted interventions. Cerebral white matter lesions and age-related 
myelin sheath degeneration have been associated with slowed pro-
cessing speed as well as slowed gait speed in older adults (16–18). 
Recent data in animal models have supported these findings (19). 
Given the poorer psychomotor speed we observed among individu-
als with high levels of IL-6, we hypothesize that elevated IL-6 may 
result in microvascular changes in white matter integrity and myeli-
nation of axons. Myelin sheaths are a protective layer of lipid or fat 
that coats the axon to speed the transmission of signals from one 
neuron to another. Damage to the myelin sheaths results in poor 
propagation of signals between neurons and may possibly lead to 
reductions in reaction times and speed of mental processing. Related 
research in WHAS II guided this hypothesis by showing a benefit 
of high cholesterol on psychomotor speed (20). We suggested that 
high cholesterol levels, in older adults, might counteract the nega-
tive effects of the natural aging process, such as increased inflamma-
tion, by preventing myelin deterioration (20). Further neuroimaging 
studies are needed to confirm these hypothesized mechanisms among 
those with cognitive impairment.
In an effort to further characterize this mechanistic pathway, oth-
ers have examined the modifying effect of inflammation on metabolic 
syndrome and cognitive decline, and they found that the association 
was greatest among individuals with high levels of inflammation 
(21). Additional studies are needed to explore the effects of inflam-
mation on cognition, and other potential modifying factors, such as 
cholesterol.
In this study, we found an association with IL-6, but not CRP. 
Dissimilar findings are expected. CRP, although sensitive, is a non-
specific marker of inflammation (22). In a comprehensive analysis 
of inflammatory markers, researchers found that compared with 
CRP, higher IL-6 levels were more strongly associated with declines 
in physical and cognitive functions and incident CVD events (23). 
These seemingly stronger associations with IL-6, compared with 
CRP, have been replicated in studies of ischemic heart disease (24), 
diabetes (25), and non-AD (3). Furthermore, there are data to sug-
gest that cytokines, including IL-6, are readily able to cross the 
blood–brain barrier. Activation of the peripheral immune system, 
as in the case of a bacterial infection, may induce a rapid release 
of cytokines and, if severe enough or amongst immune-comprised 
individuals, such as older adults, a prolonged neuroinflammatory 
response can occur peripherally and in the brain (26). Such a pro-
longed neuroinflammatory response in the brain has been linked to 
memory impairment (26).
These results are not without some limitations. First, the study 
population is community-dwelling older adult women who had 
intact baseline cognitive function, minimal functional limitations 
and were highly educated. Thus, the results may be less generaliz-
able to more cognitively and functionally vulnerable populations. 
In addition, because this is a study of women, these results may 
not be extrapolated to men. However, this information is valuable 
considering the greater longevity among women compared with 
men and their greater susceptibility to living with disabling chronic 
conditions. Second, there are no defined clinical cut points for IL-6 
and CRP in older adults. IL-6 and CRP were classified in this study 
according to the statistical distribution in our cohort and defined as 
low, medium, and high. This may result in misclassification of risk; 
however, a cut point of 2.5 pg/mL is evidenced as a point above 
which there is a much higher risk of developing adverse outcomes 
(27,28). A time-varying analysis of IL-6 or CRP was not conducted 
due to the missing data in later rounds of follow-up. Considering 
the acute fluctuations of inflammatory markers, future analyses 
should incorporate time-varying effects of IL-6 and CRP to improve 
Table 2. Baseline Distribution of Cognitive Test Scores Across Tertiles of IL-6
Cognitive Test Low IL-6 (<2.34 pg/mL), 
N = 96
Moderate IL-6 (2.34–3.42 pg/mL), 
N = 103
High IL-6 (>3.42 pg/mL), 
N = 137
p Value
Memory: HVLT—Immediate,  
mean ± SD (range)
23.6 ± 5.1 (11–35) 23.1 ± 5.1 (8–33) 22.5 ± 4.9 (7–32) .27
Memory: HVLT—Delayed,  
mean ± SD (range)
8.5 ± 2.5 (0–12) 8.3 ± 2.9 (0–12) 8.1 ± 2.5 (0–12) .25
Psychomotor speed: TMT— 
Part A*, mean ± SD (range)
35.0 ± 11.1 (12.7–65.5) 37.4 ± 12.8 (12.3–72.7) 36.3 ± 13.2 (9.4–84.7) .55
Executive function: TMT— 
Part B*, mean ± SD (range)
14.6 ± 5.6 (3.4–30.6) 14.4 ± 6.1 (3.4–32.7) 13.5 ± 5.7 (4.6–30.6) .34
Notes: HVLT = Hopkins Verbal Learning Test; IL-6 = interleukin-6; TMT = Trail Making Test.
*Speed to task completion = number of connections/min (higher scores are better).
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accuracy with tested outcomes. A better understanding of the bio-
logical mechanism for the effects of inflammation on cognitive out-
comes may warrant the use of a lag analysis when incorporating 
inflammation as time-varying. Third, the sample size for this analysis, 
specifically when categorizing the biomarkers, is small and we may 
have insufficient power to detect significant differences in cognitive 
function between tertiles of the inflammatory biomarkers. Declines 
in psychomotor speed may be due to new CVD events (eg, stroke) 
in this initially high-functioning group of women. Adjudicated inci-
dent events are not available in this cohort and are a limitation of 
this study. Self-reported incidence of events is available for a few 
diseases (Supplementary Table S5); however, the data have not been 
considered reliable and were, therefore, not included in this analy-
sis. In addition, imaging and postmortem data from other observa-
tional studies suggest that the form of CVD we are hypothesizing as 
deleterious is subclinical and largely undetected when measured by 
incident events (16,29,30). Nonetheless, the number of participants 
reporting incident stroke was small (n = 77) and would likely not 
significantly alter the results. Lastly, 25% of participants reported 
arthritis; however, <1% had difficulty completing the task due to 
arthritis or hand tremors that could plausibly affect coordination or 
fine motor movements.
Much of the literature examining the associations between 
vascular disease and cognitive outcomes has found decrements in 
processing speed. Our finding that high levels of inflammation, par-
ticularly IL-6, results in decline in processing speed could indicate a 
mechanistic pathway between vascular disease and preclinical cogni-
tive declines through chronic inflammatory processes. To further elu-
cidate this hypothesis, future studies should explore the modifying 
and mediating effects of inflammation on vascular and nonvascular 
diseases and cognitive outcomes.
Supplementary Material
Supplementary material can be found at: http://biomedgerontology.
oxfordjournals.org/
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